Page 32 - Read Online

breast carcinomas versus synchronous axillary lymph 14. Pérez-Fidalgo JA, Eroles P, Ferrer J, Bosch A, Burgués O,
node metastases: a multicenter retrospective investigation. Martínez F, Bermejo B, Lluch A, González-Angulo AM. An
Onco Targets Ther 2014;7:1267-72. evaluation of the impact of technical bias on the concordance
2. Ieni A, Barresi V, Giuffrè G, Caltabiano R, Cascone A, rate between primary and recurrent tumors in breast cancer.
Del Sordo R, Cabibi D, Zeppa P, Lanzafame S, Sidoni A, Breast 2013;22:974-9.
Franco V, Tuccari G. Letter to the Editor regarding the paper 15. Turner NH, Di Leo A. HER2 discordance between primary
by Aurilio et al. A meta-analysis of oestrogen receptor, and metastatic breast cancer: assessing the clinical impact.
progesterone receptor and human epidermal growth factor Cancer Treat Rev 2013;39:947-57.
receptor 2 discordance between primary breast cancer and 16. Idirisinghe PK, Thike AA, Cheok PY, Tse GM, Lui PC,
metastases. Eur J Cancer 2014;50:1035-7. Fook-Chong S, Wong NS, Tan PH. Hormone receptor and
3. Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D. c-ERBB2 status in distant metastatic and locally recurrent
Quantitative analysis of changes in ER, PR and HER2 breast cancer. Pathologic correlations and clinical signifi cance.
expression in primary breast cancer and paired nodal Am J Clin Pathol 2010;133:416-29.
metastases. Ann Oncol 2010;21:1254-61. 17. Kim JH, Kim MA, Lee HS, Kim WH. Comparative analysis
4. Chan A, Morey A, Brown B, Hastrich D, Willsher P, of protein expressions in primary and metastatic gastric
Ingram D. A retrospective study investigating the rate carcinomas. Hum Pathol 2009;40:314-22.
of HER2 discordance between primary breast carcinoma 18. Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A,
and locoregional or metastatic disease. BMC Cancer Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I,
2012;12:555. Schlake W, Höfl er H, Kreipe HH. HER2 diagnostics in
5. Hoefnagel LD, Moelans CB, Meijer SL, van Slooten HJ, gastric cancer-guideline validation and development of
Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, standardized immunohistochemical testing. Virchows Arch
Nagtegaal ID Oudejans J, van der Valk P, van Gils CH, 2010;457:299-307.
van der Wall E, van Diest PJ. Prognostic value of estrogen 19. Kim MA, Lee HJ, Yang HK, Bang YJ, Kim WH.
receptor α and progesterone receptor conversion in distant Heterogeneous amplifi cation of ERBB2 in primary lesions
breast cancer metastases. Cancer 2012;118:4929-35. is responsible for the discordant ERBB2 status of primary
6. Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, and metastatic lesions in gastric carcinoma. Histopathology
Curigliano G, Adamoli L, Munzone E, Sciandivasci A, 2011;59:822-31.
De Vita F, Goldhirsch A, Nolè F. A meta-analysis of 20. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY,
oestrogen receptor, progesterone receptor and human Penault-Llorca F, van de Vijver M, Viale G. HER2 testing
epidermal growth factor receptor 2 discordance between in gastric cancer: a practical approach. Mod Pathol
primary breast cancer and metastases. Eur J Cancer 2012;25:637-50.
2014;50:277-89. 21. Giuffrè G, Ieni A, Barresi V, Caruso RA, Tuccari G.
7. Curtit E, Nerich V, Mansi L, Chaigneau L, Cals L, HER2 status in unusual histological variants of gastric
Villanueva C, Bazan F, Montcuquet P, Meneveau N, Perrin S, adenocarcinomas. J Clin Pathol 2012;65:237-41.
Algros MP, Pivot X. Discordances in estrogen receptor 22. Barresi V, Giuffrè G, Caruso RA, Tuccari G. HER2 status
status, progesterone receptor status, and HER2 status in rarer histologic types of gastric adenocarcinomas.
between primary breast cancer and metastasis. Oncologist Arch Pathol Lab Med 2013;137:741.
2013;18:667-74. 23. Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C,
8. Penault-Llorca F, Coudry RA, Hanna WM, Osamura RY, Tamagnini I, Gardini G, Nizzoli R, Leonardi F, Gasparro D,
Rüschoff J, Viale G. Experts’ opinion: Recommendations for Camisa R, Cavalli S, Silini EM, Ardizzoni A. Comparison of
retesting breast cancer metastases for HER2 and hormone HER2 status in primary and paired metastatic sites of gastric
receptor status. Breast 2013;22:200-2. carcinoma. Br J Cancer 2011;104:1372-6.
9. Regitnig P, Schippinger W, Lindbauer M, Samonigg H, 24. Kochi M, Fujii M, Masuda S, Kanamori N, Mihara Y, Funada T,
Lax SF. Change of HER-2/neu status in a subset of Tamegai H, Watanabe M, Suda H, Takayama T. Differing
distant metastases from breast carcinomas. J Pathol deregulation of HER2 in primary gastric cancer and synchronous
2004;203:918-26. related metastatic lymph nodes. Diagn Pathol 2013;8:191.
10. Santinelli A, Pisa E, Stramazzotti D, Fabris G. HER-2 25. Marx AH, Tharun L, Muth J, Dancau AM, Simon R,
status discrepancy between primary breast cancer and Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH,
metastatic sites. Impact on target therapy. Int J Cancer Bokemeyer C, Izbicki JR, Sauter G. HER-2 amplifi cation
2008;122:999-1004. is highly homogenous in gastric cancer. Hum Pathol
11. Lindström LS, Karlsson E, Wilking UM, Johansson U, 2009;40:769-77.
Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J. 26. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M,
Clinically used breast cancer markers such as estrogen Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of
receptor, progesterone receptor, and human epidermal growth a HER2 scoring system for gastric cancer: results from a
factor receptor 2 are unstable throughout tumor progression. validation study. Histopathology 2008;52:797-805.
J Clin Oncol 2012;30:2601-8. 27. Ataseven B, Gologan D, Gunesch A, Kehl V, Hoegel B,
12. Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD. Beer M, Eiermann W. HER2/neu, Topoisomerase 2a,
HER2 discordance between primary breast cancer and its paired Estrogen and Progesterone Receptors: Discordance between
metastasis: tumor biology or test artefact? Insights through Primary Breast Cancer and Metastatic Axillary Lymph
meta-analysis. Breast Cancer Res Treat 2011;129:659-74. Node in Expression and Amplifi cation Characteristics.
13. Cardoso F, Harbeck N, Fallowfi eld L, Kyriakides S, Breast Care (Basel) 2012;7:465-70.
Senkus E. ESMO Guidelines Working Group. Locally 28. Falck AK, Bendahl PO, Chebil G, Olsson H, Fernö M,
recurrent or metastatic breast cancer: ESMO Clinical Practice Rydén L. Biomarker expression and St Gallen molecular
Guidelines for diagnosis, treatment and follow-up. Ann Oncol subtype classifi cation in primary tumours, synchronous
2012;23 Suppl 7:vii11-9. lymph node metastases and asynchronous relapses in

Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 1 ¦ April 15, 2015 ¦ 25